BTOG 2019 | SABR improves outcomes for stage 1 lung cancer

Iain Phillips, MBBS, BSc, MSc, MRCP, FRCR, of NHS Lothian, Edinburgh, UK, discusses his group’s work on investigating outcomes after stereotactic ablative body radiotherapy (SABR) for stage 1 lung cancer from the British Thoracic Oncology Group (BTOG) 2019 Annual Conference, held in Dublin, Ireland. Dr Phillips highlights the benefits of SABR compared to standard radiotherapy.